Objective To investigate the efficacy and safety of sacubatrovalsartan sodium combined with emergency percutaneous coronary intervention（PCI）in patients with acute myocardial infarction（AMI）. Methods A total of 348 AMI patients，who had hospitalized in TEDA International Cardiovascular Hospital and had received emergency percutaneous coronary intervention from January 2020 to December 2020 were chosen. According to the postprocedural uses of different medications，the patients were assigned to a study group（n = 165，oral sacubatro⁃ valsartan sodium tablets）or a control group（n = 183，oral ramipril）. The changes in left ventricular end systolic diameter（LVESD），left ventricular end diastolic diameter（LVEDD）and left ventricular ejection fraction（LVEF）， and the rates of adverse cardiovascular events and adverse reactions were observed and compared between the two groups. Results All the patients were follow up for an average of（20.46 ± 3.58）weeks. LVESD and LVEDD sig⁃ nificantly shortened and LVEF significantly increased in both groups as compared with the baselines（P < 0.05）. LVESD and LVEDD were significantly lower and LVEF was evidently higher in the study group than in the control group（P < 0.05 for all comparisons）. The incidence of adverse events in the study group was significantly lower than that in the control group（8.49% vs. 16.94%，P < 0.05）. No adverse reactions were occurred in both groups. Conclusions Sacubatrovalsartan sodium combined with emergency percutaneous coronary intervention can improve the clinical efficacy and left ventricular remodeling in AMI patients.